What is Boehringer Ingelheims policy on clinical trial information disclosure?
Boehringer Ingelheim has a general policy of transparency with publication of clinical trial results. We recognize that there are important public health benefits associated with making clinical trial information more widely available to healthcare professionals and patients. Such disclosure, however, must maintain protection for intellectual property and contract rights as well as conform to the regulations in relevant countries. Boehringer Ingelheim supports the joint global position of the research-based pharmaceutical industry published by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and is committed to the agreed principles.
Boehringer Ingelheim has a general policy of transparency with publications of clinical trial results. We recognize that there are important public health benefits associated with making clinical trial information more widely available to healthcare professionals and patients. Such disclosure, however, must maintain protections for intellectual property and contract rights as well as conform to the regulations in relevant countries. Boehringer Ingelheim supports the joint global position of the research-based pharmaceutical industry published by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on 06 January 2005 and is committed to the agreed principles.
Boehringer Ingelheim has a general policy of transparency with publications of clinical trial results. We recognize that there are important public health benefits associated with making clinical trial information more widely available to healthcare professionals and patients. Such disclosure, however, must maintain protections for intellectual property and contract rights as well as conform to the regulations in relevant countries. Boehringer Ingelheim supports the joint global position of the research-based pharmaceutical industry published by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on 06 January 2005, updated on 18 November 2008, and is committed to the agreed principles. The disclosure process is based upon the requirements outlined in the global industry position paper of the IFPMA, the requirements by the United States Food and Drug Administration Amendments Act of 2007 (FDAAA), and the United States state of Maine law regarding the R
